Primary Care Companion for CNS Disorders Primary Care Companion for CNS Disorders

The Primary
Care Companionfor CNS Disorders

Advancing primary care with essential research and insights into CNS disorders

Back to top Open menu arrow
About Authors Archives Current Issue
PCC
Withdrawal Psychosis During a Digital Detoxification Camp
Case Report

October 1, 2024

A 24-year-old woman with a history of depression, anxiety, and ADHD presented with ongoing auditory and visual hallucinations and aggressive behavior that manifested while she was undergoing treatment at…
PCC
Breast Cancer and Depression
Systematic Review

September 26, 2024

This scoping review explores depression prevalence, correlates, impact, and interventions in breast cancer patients, with a focus on the Indian context.
PCC
Relationship Between Social Isolation and Substance Abuse
Original Research

September 24, 2024

This study highlights the connection between social isolation and substance use disorder, emphasizing the need to address social isolation as a public health issue.

Explore Special Sections

View all topics
Rounds in the General Hospital

Case Reports

PCC
Transient Cola Use Disorder in a Patient With Schizophrenia
Case Report

September 12, 2024

This case describes a transient cola addiction, lasting around 5 months, in a patient with a 27-year history of schizophrenia.
PCC
Stated Versus Demonstrated Capacity
Case Report

September 10, 2024

The authors present a complex case involving a patient with HIV, where decisional capacity was questioned based on her stated versus demonstrated capacity.
PCC
Montelukast-Induced Behavioral Problems in a Child With Asthma
Case Report

September 5, 2024

The authors report a case of a 6-year-old boy who developed acute behavioral disturbances after being prescribed montelukast prophylaxis for bronchial asthma.
PCC
Recurrence of Tolosa-Hunt Syndrome
Case Report

September 3, 2024

The authors present a unique presentation of ipsilateral recurrence of Tolosa Hunt syndrome involving the sixth cranial nerve in a 64-year-old man.
PCC
Adalimumab-Associated Depressive Symptoms in VAIHS
Case Report

August 29, 2024

A 16-year-old boy with vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome, who was taking adalimumab, presented with features of depression.
PCC
Unremitting Nausea Due to Lurasidone After Semaglutide Initiation
Case Report

August 29, 2024

The potential drug interaction between lurasidone and semaglutide causing new intolerable nausea following lurasidone administration is described in the case of a 35-year-old woman.

Lorem Ipsum Title Here

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient. Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient.

Go to ASCP

More PCC Articles

JCP
Ketamine/Esketamine in Bipolar Depression in a Clinical Setting
Original Research

October 2, 2024

In a small sample of patients with bipolar depression treated with ketamine/esketamine, no evidence of mania or hypomania was seen during acute treatment.
JCP
Suicide Risk Evaluation and Advanced AI Models
Original Research

October 2, 2024

This study explored how ChatGPT-3.5 and ChatGPT-4 assess suicide risk factors like previous attempts, gender, and age, focusing on their predictions about different types of suicidal behavior.
JCP
Algorithms for TRD Treatment Success
Insights

September 27, 2024

Dr. Nolan Williams delves into the innovative Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for treating resistant depression. Explore groundbreaking research, clinical trials, and the transformative potential of personalized brain…
JCP
Changes in Cognition in Patients With Schizophrenia
Meta-Analysis

September 25, 2024

Only marginal improvements in cognition were seen over time; the greatest were achieved for patients with an illness duration shorter than 10 years.
JCP
Regression: Understanding What Covariates and Confounds Do in Adjusted Analyses
Clinical and Practical Psychopharmacology

September 18, 2024

Basic terms and concepts of regression analysis are presented, as well as three useful examples that involve readers in learning how regressions work.
JCP
Diagnostic Assessment via Telehealth vs Face-to-Face
Systematic Review

September 16, 2024

Several small studies suggest that telehealth holds promise for psychiatric assessments, especially when in-person evaluations are not feasible.
JCP
Medication Use and Lines of Treatment in Patients With Insomnia Disorder
Original Research

September 11, 2024

In this Canadian study, the annual cost of medications for insomnia was $54.8 million, and $30.3 million (55.2%) met inappropriate medication use criteria.
JCP
Bridge Symptoms Between Borderline Personality and PTSD
Original Research

September 9, 2024

Self-aggression, feelings of emptiness, dissociation, and feelings of detachment were found to be bridge symptoms between borderline personality disorder and PTSD. Targeting these might allow better prevention and management…
JCP
Collaborative vs Specialty Care for Depression or Anxiety
Original Research

September 4, 2024

Model effects at 6 months revealed that patients assigned to collaborative care showed significantly greater improvement than those assigned to specialty psychiatry.
JCP
Baseline Cognition Is Not Associated With Depression Outcomes in Vortioxetine
Original Research

September 4, 2024

This study suggests that cognitive function does not moderate depression outcomes in vortioxetine, with results comparable to other antidepressants.
JCP
Perinatal Timing of OCD Onset
Original Research

August 28, 2024

Findings show that OCD is most likely to begin in the early postpartum, with a rapid transition from symptoms to disorder. People with pre-existing OCD are vulnerable to symptom…
JCP
SSRI Discontinuation and AUD Relapse
Case Report

August 26, 2024

A man with AUD achieves sobriety on treatment with an SSRI and naltrexone, but then stops taking the SSRI to participate in a psilocybin “ceremony.” What factors contributed to…